Vyome shares surge 10.89% intraday after securing $5.29M in minimal dilution funding for VT-1953 Phase 3 trials.

Vyome Holdings (HIND) surged 10.89% intraday after announcing it successfully funded its VT-1953 Phase 3 study budget through its ATM facility, raising $5.29 million with minimal dilution. The company sold 1.09 million shares at an average price of $5.00, a 59.2% premium to the prior day’s close, ensuring sufficient liquidity to deliver interim Phase 3 results for its MFW drug by mid-2027. Management emphasized the funding’s favorable terms—no warrants or investor rights—highlighting a focus on shareholder value and positioning VT-1953 as a potential $1 billion asset post-trials. The update reinforced confidence in the company’s execution plan and financial discipline, directly aligning with the intraday price rally.